backed by the best
-
Their belief in our vision to transform the injection experience underscores the potential of our innovative platform. These partnerships provide us with the necessary resources to advance and amplify our affordable, stress-free patient solutions. Together, we are paving the way for a future where healthcare is as simple as pushing a button. With the support of our investors, we are poised to redefine the standard of care across the sterile injectables market.
“An investment in Pirouette is not just promising; it's a unique opportunity seldom seen in the medical industry, where the public can directly invest in an emerging medical company that will save lives and enable affordable healthcare. Pirouette is poised to revolutionize the $824 Billion injectables market and transform how life-saving injections are administered and accessed.”
-Arunas Chesonis
Managing Partner, Safar Partners
“An investment in Pirouette is not just promising; it's a unique opportunity seldom seen in the medical industry, where the public can directly invest in an emerging medical company that will save lives and enable affordable healthcare. Pirouette is poised to revolutionize the $824 Billion injectables market and transform how life-saving injections are administered and accessed.”
-Arunas Chesonis
Managing Partner, Safar Partners
“The founders themselves are so well qualified to work on this specific problem. As an investor, you always want to see progress. The thing that kills companies is standing still and this is not a team who under any amount of stress is going to stop working on this product. They not only have the conviction, but they have the operational chops to do so.”
-Surbhi Sarna
Biotech Partner, Y Combinator
“The founders themselves are so well qualified to work on this specific problem. As an investor, you always want to see progress. The thing that kills companies is standing still and this is not a team who under any amount of stress is going to stop working on this product. They not only have the conviction, but they have the operational chops to do so.”
-Surbhi Sarna
Biotech Partner, Y Combinator